# OnCo record imetelstat (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/imetelstat/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "imetelstat" ;
  schema:name "Imetelstat"@en ;
  schema:description "Imetelstat is a lipid-linked oligonucleotide that binds the RNA template of telomerase, the enzyme cancer cells use to stay immortal, and it is the first telomerase inhibitor approved for any cancer. In lower-risk myelodysplastic syndromes it freed 40% of transfusion-dependent patients from transfusions for at least eight weeks versus 15% on placebo, once growth factors have failed."@en ;
  schema:url <https://onco.cc/drugs/imetelstat/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Imetelstat> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21083935> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(23)01724-5>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=imetelstat> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Telomerase inhibitor (oligonucleotide)" ;
  schema:alternateName "Rytelo" ;
  onco:approval "US 2024: Low- to intermediate-1-risk MDS with transfusion-dependent anaemia after ESA failure", "EU 2025: Lower-risk MDS transfusion-dependent anaemia" ;
  onco:cancers <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/mds-lower-risk/> ;
  onco:technologies <https://onco.cc/technologies/antisense-sirna/>, <https://onco.cc/technologies/transfusion-support/> ;
  onco:companies <https://onco.cc/companies/geron/> ;
  onco:trials <https://onco.cc/trials/nct05583552/>, <https://onco.cc/trials/impactmf/> .